Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Trial Profile

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs QR-421a (Primary)
  • Indications Usher syndromes
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms STELLAR
  • Sponsors ProQR Therapeutics
  • Most Recent Events

    • 29 Jan 2019 According to the ProQR Therapeutics, updates from the study announced in ProQR Vision 2023 strategy and will be presented at an R&D day event.
    • 17 Dec 2018 Status changed from planning to not yet recruiting.
    • 04 Dec 2018 According to a ProQR media release, US FDA has cleared the IND application for QR-421a, the company plans to start enrolling patients in this trial in the coming months with preliminary data expected in mid-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top